medigraphic.com
ISSN 1027-2852 (Electronic)
ISSN 0864-4551 (Print)

2016, Number 2

<< Back Next >>

Biotecnol Apl 2016; 33 (2)

The International Liver Congress, April 13-17th, 2016, Barcelona, Spain

Aguilar RJC

Language: English
References: 19
Page: 2501-2505
PDF size: 228.74 Kb.


ABSTRACT

IThis report highlights the recent discoveries presented at the 2016 Annual Meeting of the European Association for the Study of the Liver (EASL), called the International Liver Congress (ILC), which was held in Barcelona, Spain, from April 13th to 17th. Major topics were: viral hepatitis; cirrhosis; immunology & inflammation; transplantation; tumours; fatty liver disease; drug induced diseases; diagnostics; molecular and cellular biology; paediatric liver diseases; clinical trials; autoimmune diseases; fibrosis markers and public health. The most relevant findings regarding the new products for the treatment of chronic hepatitis B, and also new developments in hepatitis C and D are discussed.


REFERENCES

  1. Wong GLH, Tse YK, Wong V, Yip T, Chan H. Incidences of all malignancies in patients with chronic hepatitis B receiving long-term oral nucleos(t)ide analogue treatment – a study of 45’299 subjects. Section: Viral Hepatitis; Sub-section: Hepatitis B & D -clinical (therapy, new compounds, resistance). Program and abstracts of the 51st Annual Meeting of the European Association for the Study of the Liver; April 13-17, 2016; Barcelona, Spain. Abstract PS052.

  2. European Association for the Study of the Liver. Treatment for chronic hepatitis B linked to increased rates of colorectal and cervical cancer. ScienceDaily. 2016 Apr 15 [cited 2016 May 30]. Available from: www.sciencedaily.com/releases/2016/04/160415081420.htm

  3. Johnson K. Release raises false alarm over Hep B meds and cancer risk. Medscape. 2016 Apr 22 [cited 2016 May 30]. Available from: http://www.medscape.com/viewarticle/862371

  4. Jiang L, Wu X, He F, Liu Y, Hu X, Takeda S, et al. Genetic Evidence for Genotoxic Effect of Entecavir, an Anti-Hepatitis B Virus Nucleotide Analog. PLoS One. 2016;11(1):e0147440.

  5. Food and Drug Administration. Baraclude Product Insert NDA 21-797-S-001. 2007 [cited 2016 May 22]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021797s001,021798s001lbl.pdf

  6. Food and Drug Administration. Viread Product Insert. 2012 [cited 2016 May 22]. Available from: http://www.accessdata. fda.gov/drugsatfda_docs/label/2012/02 1356s042,022577s002lbl.pdf

  7. Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, doubleblind, phase 3, non-inferiority trials. Lancet. 2015;385(9987):2606-15.

  8. Buti M, Gane E, Seto WK, Chan HLY, Chuang WL, Stepanova T, et al. A phase III study of Tenofovir Alafenamide compared with Tenofovir Disoproxil Fumarate in patients with HBeAg-negative, chronic hepatitis B: Week 48 efficacy and safety results. Program and abstracts of the 51st Annual Meeting of the European Association for the Study of the Liver; April 13-17, 2016; Barcelona, Spain. Abstract GS06.

  9. Chan HLY, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, et al. A phase III study of Tenofovir Alafenamide compared with Tenofovir Disoproxil Fumarate in patients with HBeAg-positive, chronic hepatitis B: Week 48 efficacy and safety results. Program and abstracts of the 51st Annual Meeting of the European Association for the Study of the Liver; April 13-17, 2016; Barcelona, Spain. Abstract GS12.

  10. Chang Y, Lee JH, Nam JY, Ahn H, Cho H, Cho Y, et al. Nucleos(t)ide analogue treatment for immune tolerant phase of Chronic Hepatitis B patients prolongs overall survival and reduces the risk of hepatocellular carcinoma and cirrhosis: a real-life study. Program and abstracts of the 51st Annual Meeting of the European Association for the Study of the Liver; April 13-17, 2016; Barcelona, Spain. Abstract PS049.

  11. Yuen MF, Kim DJ, Weilert F, Chan HLY, Lalezari JP, Hwang SG, et al. NVR 3-778, A first in class HBV core inhibitor, alone and in combination with Peg-Interferon (PegIFN), in treatment-naïve HBeAgpositive patients: Early reductions in HBV DNA and HBeAg. Program and abstracts of the 51st Annual Meeting of the European Association for the Study of the Liver; April 13-17, 2016; Barcelona, Spain. Abstract, Late Breaker.

  12. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77-87.

  13. Kwo PY, Wyles DL, Wang S, Poordad F, Gane E, Maliakkal B, et al. SURVEYOR-II: 100% SVR12 with ABT-493 and ABT-530 with or without ribavirin in treatment-naive HCV genotype 3-infected patients with cirrhosis. Program and abstracts of the 51st Annual Meeting of the European Association for the Study of the Liver; April 13-17, 2016; Barcelona, Spain. Abstract LBO1.

  14. Wang GP, Reeves JD, Terrault N, Lim JK, Morelli G, Kuo A, et al. Prevalence and impact of baseline resistance-associated variants on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection: HCV-TARGET interim analysis. Program and abstracts of the 51st Annual Meeting of the European Association for the Study of the Liver; April 13-17, 2016; Barcelona, Spain. Abstract PS102.

  15. Deterding K, Spinner C, Schott E, Welzel T, Gerken G, Klinker H, e. Six weeks of sofosbuvir/ledipasvir (SOF/ LDV) are sufficient to treat acute hepatitis C virus genotype 1 monoinfection: the HEPNET Acute HCV IV Study. Program and abstracts of the 51st Annual Meeting of the European Association for the Study of the Liver; April 13-17, 2016; Barcelona, Spain. Abstract LBO8.

  16. Fernández-Carrillo C, Lens S, Llop E, Pascasio JM, Fernandez I, Baliellas C, et al. Treatment of hepatitis C virus in patients with advanced cirrhosis: always justified? Analysis of the HEPA-C registry. Program and abstracts of the 51st Annual Meeting of the European Association for the Study of the Liver; April 13-17, 2016; Barcelona, Spain. Abstract GS01.

  17. Kattakushy S, Gross C, Teferi G, Jenkins V, Silk R, Akoth E, et al. A novel task shifting model to expand the HCV care continuum: the ascend investigation. Program and abstracts of the 51st Annual Meeting of the European Association for the Study of the Liver; April 13-17, 2016; Barcelona, Spain. Abstract LBP524.

  18. Wrankle A, Serrano BC, Heidrich B, Kirschner J, Bremer B, Hardtke S, et al. Does antiviral treatment affect the clinical long-term outcome of Hepatitis Delta? Section: Viral Hepatitis; Sub-section: Hepatitis B & D –clinical (therapy, new compounds, resistance). Program and abstracts of the 51st Annual Meeting of the European Association for the Study of the Liver; April 13-17, 2016; Barcelona, Spain. Abstract GS053.

  19. European Association for the Study of the Liver. Study demonstrates benefits of existing treatment for hepatitis D patients. ScienceDaily. 2016 Apr 15 [cited 2016 May 30]. Available from: https://www.sciencedaily.com/releases/ 2016/04/160415081411.htm




2020     |     www.medigraphic.com